Carnegie Investment Counsel’s Editas Medicine EDIT Stock Holding History

Carnegie Investment Counsel’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,479	Closed	-$244K	–	457
2020 Q4	$244K	Buy	+3,479	New	+$143K	0.01%	386
2020 Q1	–	Sell	-36,590	Closed	-$1.08M	–	403
2019 Q4	$1.08M	Sell	36,590 -10,150	-22%	-$253K	0.06%	217
2019 Q3	$1.06M	Buy	46,740 +6,750	+17%	+$167K	0.07%	211
2019 Q2	$989K	Buy	+39,990	New	+$955K	0.06%	216
2018 Q4	–	Sell	-46,050	Closed	-$1.33M	–	376
2018 Q3	$1.33M	Buy	46,050 +9,230	+25%	+$298K	0.11%	176
2018 Q2	$1.09M	Sell	36,820 -5,400	-13%	-$191K	0.08%	198
2018 Q1	$1.49M	Buy	42,220 +2,620	+7%	+$93.4K	0.12%	159
2017 Q4	$1.45M	Buy	+39,600	New	+$997K	0.13%	181

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Carnegie Investment Counsel's EDIT Position: Q1 2021 in Review

Carnegie Investment Counsel sold out of Editas Medicine (EDIT) in Q1 2021, closing a stake of 3,479 shares — an estimated $244K sold.

Carnegie Investment Counsel first reported a position in EDIT in Q4 2017 and held it in 8 quarters. The position peaked at $1.49M in Q1 2018. 312 funds tracked by Wall St. Rank hold EDIT as of Q1 2021.

Carnegie Investment Counsel reported no remaining Editas Medicine position as of Q1 2021 after selling out during the quarter.
Carnegie Investment Counsel sold 3,479 Editas Medicine shares in Q1 2021, an estimated $244K.
Carnegie Investment Counsel first reported a position in Editas Medicine in Q4 2017 and held it in 8 quarters.
Carnegie Investment Counsel's Editas Medicine position peaked at $1.49M in Q1 2018.
312 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2021.

Based on Carnegie Investment Counsel's 13F filing for Q1 2021, filed 12 Apr 2021.